We examined the basis for the absence in cystic fibrosis (CF) patients of opsonic antibodies to the mucoid exopolysaccharide (MEP) antigen surrounding Pseudomonas aeruginosa that infect these patients. Opsonic antibodies to MEP are found in sera of the minority of CF patients that remain noncolonized into the second to fourth decades of life and protect rodents from chronic P. aeruginosa endobronchial infections. High titers of nonopsonic antibodies to MEP are found in P. aeruginosa-infected CF patients. Immunization of mice with doses of MEP that provoke only nonopsonic antibodies elicited CD3 +, CD8 +, T cell receptor a# receptor +, major histocompatibility complex-unrestricted cytotoxic lymphocytes specific for hybridoma cells producing opsonic but not nonopsonic antibodies. Cytotoxicity was dependent on immune complexes on the surface of the T cells. Normal murine T cells could be activated by concanavalin A and sensitized with immune complexes for cytotoxic killing of hybridoma targets. CF patients infected with P. aeruginosa had serum immune complexes that sensitized concanavalin A-activated human T cells to kill murine hybridoma cells producing opsonic but not nonopsonic antibody. These results could explain the absence in infected CF patients of MEP-specific opsonins, an occurrence that accompanies the persistence of this infectious state. (J. Clin. Invest. 1993. 91:1079-1087 Key words: endobronchial infections * Fc receptors -immunosuppression * mucoid exopolysaccharide* phagocytosis.
Introduction
The appearance of chronic infections causing diseases such as AIDS, syphilis, and Lyme disease in previously immunocompetent individuals suggests that specific immune defects occur that interfere with the production of appropriate effectors to eliminate the pathogen. For example, the development of the chronic hepatitis B virus carrier state has been reported by Bar- naba et al. ( 1 ) to be associated with the presence of HLA class I-restricted cytotoxic T lymphocytes (CTL)' that kill B cells producing virus-specific neutralizing antibodies. Acquisition of persistent pulmonary infection with mucoid strains ofPseudomonas aeruginosa among cystic fibrosis (CF) patients remains the major complication leading to morbidity and death (2, 3) . Persistence of the pathogen despite an intense immune response to bacterial antigens (4) (5) (6) (7) (8) suggests an immunologic defect specific to mucoid P. aeruginosa cells.
The outer bacterial coat of mucoid P. aeruginosa, termed mucoid exopolysaccharide (MEP) or alginate, is a major target for antibodies that mediate opsonic killing of the bacteria by leukocytes and complement (9, 10) . However, antibodies that bind to MEP antigen but fail to mediate opsonic killing (nonopsonic antibodies) are frequently encountered among younger CF patients before the onset of infection (9) and are seen at elevated titers among chronically infected patients, who also fail to produce opsonic antibodies to MEP in response to infection (9) . A small number (< 5%) of CF patients escape this seemingly inevitable colonization by the second decade of life, and analysis of 16 of these patients showed that 88% had opsonic antibodies specific to MEP, indicating an association between the presence of opsonic antibodies and resistance to infection (9) . Comparison of the protective efficacy of monoclonal and polyclonal opsonic antibodies with that of nonopsonic antibodies in rodent models of chronic P. aeruginosa infection showed protection only in the presence of opsonic MEP-specific antibodies (10) . MEP-specific opsonic antibody differs from nonopsonic antibody by depositing high levels of the critical complement opsonins C3b and C3bi on the outer bacterial surface, with most of these C3 fragments attached to the MEP ( 1). Thus, strategies to elicit MEP-specific opsonizing antibodies may eventually be applicable to the vaccination of CF patients against chronic P. aeruginosa infection.
The purpose of the present study was to identify specific immunologic mechanisms that may be responsible for the inability ofCF patients to generate an MEP-specific opsonic antibody response during infection with P. aeruginosa. In mice, 1-l0-,Ag doses of MEP composed of moderate sized polymers (mean coefficient of distribution [Kd] = 0.26 on a Sepharose CL4B column, approximate molecular size 400 kD) elicit opsonic antibody, whereas doses . 50 ,ug elicit only nonopsonic antibodies ( 12 ) . These antibodies do not differ by isotype, but are directed at different epitopes on the MEP antigen (9, 1 1 ) and differ in their ability to deposit covalently linked C3 fragments onto the bacterial surface ( 11) . After an initial 5O-Atg dose, a booster dose of 1 jig fails to elicit opsonic antibodies in these mice, and this inability to produce opsonic antibodies could be adoptively transferred to nonimmune mice by splenic T cells ( 12) . In light of recent reports by various investigators ( 1, 13, 14) that T cells can kill B cells, we investigated whether T cells elicited in response to immunization with high doses of MEP could kill hybridoma cells producing MEP-specific opsonic and nonopsonic antibody.
Methods
Bacterial strains and antigens. Mucoid P. aeruginosa strain 2192, originally obtained from the sputum of a CF patient, was used to isolate MEP antigen as described ( 12) . The MEP used to immunize mice for studies ofcytotoxic T cell activity had a Kd < 0.3 (approximate molecular size < 300 kD) and provoked only nonopsonic antibodies to MEP when given at doses of50 ,g per mouse. High molecular weight polysaccharide from P. aeruginosa was also prepared as described ( 15 ) .
Hybridoma cells. Hybridoma cells secreting MEP-specific opsonic and nonopsonic antibodies were obtained by standard methods after immunization of BALB/c mice with purified antigens or whole bacterial cells. The resulting monoclonal antibodies were classified as opsonic or nonopsonic using an opsonophagocytosis assay employing these antibodies along with either human peripheral blood leukocytes or murine inflammatory peritoneal cells, complement, and mucoid P. aeruginosa strain 2192 as described ( 16) Cytotoxicity assays employing human sera and cells. Sera from CF patients were used from our collection of samples obtained from patients attending the outpatient clinic at Children's Hospital, Boston. All samples were obtained after informed consent was given by either the patient or their parent. Peripheral blood was obtained from non CF volunteers giving informed consent, and mononuclear cells were recovered by separation on Mono-Poly resolving medium (ICN Biomedical, Costa Mesa, CA). Cultures of 106 lymphocytes/ml were established in RPMI medium supplemented with 10% fetal calf serum and 2.5 gg/ml Con A. Cultures were incubated for 48 h in 5% CO2 at 37°C. Viable cells were recovered by washing, manually counted in a hemocytometer after staining with trypan blue, and resuspended to 5 partner P3X. To insure that the hybridomas producing nonopsonic antibodies were susceptible to T cell lysis, splenic T cells from BALB/c mice immunized 6 days previously with 107 hybridoma cells in complete Freund's adjuvant were tested for their ability to lyse homologous and heterologous hybridoma targets. Both hybridomas secreting nonopsonic antibodies elicited cytotoxic T cells that efficiently lysed their homologous targets ( Fig. 1 B) ; the cytotoxic T cells only poorly lysed (< 8% ( 11) . Both types of unlabelled hybridoma cells inhibited, in a dose-dependent fashion, the killing of target hybridomas that produced opsonic antibodies; in contrast a hybridoma secreting irrelevant antibody failed to inhibit killing (Fig. 3) .
We next added varying amounts of MEP to cytotoxicity assays to determine further if immune complexes are involved in T cell recognition of target hybridoma cells. Addition of MEP antigen up to 70 ,ug/ml enhanced target cell lysis in a dose-dependent fashion (Fig. 4) . Enhancement of lysis was specific to hybridomas producing opsonic antibodies and addition of MEP antigen did not promote the otherwise low-level release of 5"Cr from hybridomas producing nonopsonic antibodies (Fig. 4) .
The above data implicate FcR-positive T cells armed with immune complexes composed of MEP-specific antibody and MEP antigen as the mediators of the observed cytotoxicity. Presumably the antigen component is derived from the immunizing material, but the antigen enhancement of cytotoxicity shown in Fig. 4 Concentration of inhibiting cell When we added increasing amounts of MEP antigen to T cells before their addition to labelled targets, increased lyses of the targets was observed (Fig. 5 A) . Addition of an irrelevant polysaccharide antigen failed to increase target cell lysis. This model would also predict that once the antibody on the surface ofthe T cell was saturated with antigen, the addition of further antigen to the assay should begin to interfere with the binding ofthe T cell to hybridoma targets by saturating antigen binding sites on the hybridoma targets. This would result in decreased target cell lysis. When T cells previously incubated for 1 h with 100 yg/ml of MEP antigen to saturate surface antibody (Fig. 5 A) were added to target hybridoma cells in the presence of increasing amounts of MEP antigen, a dose-dependent inhibition of lysis was observed (Fig. 5 B) . An irrelevant polysaccharide antigen had no such effect. These data support the concept that in this system cytotoxic T cell activity is dependent upon MEP antigen serving as a bridge between FcR bound antibody on the cytotoxic T cells and membrane antibody on the target hybridoma cells.
To determine further if immune complexes on the surface of the T cell were involved in recognition of target hybridoma cells, we immunized mice with 50 ,ug of MEP and 6 d later exposed isolated splenic T cells to pH 5.0 for 5-15 min, a procedure previously employed to dissociate T cell bound antibody from antibacterial T cells ( 19, 20) . Under these conditions, cytotoxic activity was restored only if both MEP-specific antibody and MEP antigen were added back to the assay (Fig. 6  A) . The antibodies could be specific for epitopes that bind ei-various combinations of MEP-specific antibody and/or MEP antigen or with nonimmune serum and MEP antigen; hybridoma cells secreting opsonic antibody to MEP served as targets. The Con A-activated T cells killed the hybridoma cells only when MEP-specific antibody and antigen were present (Fig. 7  A) . Con A-activated T cells did not kill the same heterologous targets shown in Fig. 1 B in the presence of MEP-specific antibody and antigen (not shown), nor was cytotoxic activity evident if cells were not exposed to Con A (not shown). 
aeruginosa). (B)
Immune T cells were first incubated with 100 0,g/ml of MEP, washed, To characterize the cell surface markers on the Con A-activated T cells, we performed depletion experiments using antibodies specific to T cell markers identical to those described in Fig. 2 . Like immune CTL, most ofthe Con A-activated T cells expressed the CD3, CD8, and a13 TCR antigens (Fig. 7 B) . In addition, both Con A-activated cells (Fig. 7 B) and immune T cells exposed to pH 5 for 15 min (not shown) could be depleted from reaction mixtures by monoclonal antibody 2.4G2, which is specific to the murine FcRy (22) . These experiments indicated that T cells that kill the hybridoma cells secreting opsonic antibody to P. aeruginosa MEP express the CD3, CD8, a13 TCR, and FcRy surface markers.
Role ofnonopsonic antibodies to MEP and immune complexesfound in the sera ofCFpatients in cytotoxicity. We next determined ifthe nonopsonic antibodies to MEP present in CF patient's sera before the onset of colonization (9, 18), could provide the antibody component of the immune complex needed to mediate T cell killing of 8/5 )31 cells if exogenous MEP antigen was provided. In addition, we tested whether antibodies and/or immune complexes were present in the sera of CF patients colonized with P. aeruginosa that could sensitize Con A-activated human peripheral blood T cells and mediate killing of the 8/5)31 hybridoma. Con A-activated peripheral blood T cells from volunteer blood donors were incubated with serum samples from individual CF patients lacking P. aeruginosa colonization (eight male, five female, mean age 1 1.8±10 yr, range 4-41 yr) or with serum samples from CF patients colonized for 2 2 yr with mucoid P. aeruginosa (nine male, four female, mean age 18.5±12.4 yr, range 3-39 yr). Killing of the 8/5)31 hybridoma and control M/K) 16 and P3X cell lines was evaluated in the presence or absence of added MEP antigen. Results are shown in Fig. 8 .
Sera from noncolonized CF patients, in the absence of added MEP antigen, did not mediate killing of the 8/5)31 hybridoma any better than they mediated killing ofthe control hybridoma and myeloma cell lines (Mann-Whitney U-test P values 0.27 and 0.92, respectively). However, in the presence of 5 ug MEP per well, there was significantly greater killing of the 8/5)31 targets than in its absence (paired t value -2.38, P = 0.035, two-tailed). There was no enhanced killing of the control target cell lines upon addition of MEP antigen to the noncolonized patient's sera (P 2 0.4). In the presence ofadded MEP, there was significantly more killing of the 8/5)31 cells compared with the M/K) 16 (Fig. 8, paired t value -0.02, P = 0.99, two-tailed). In both the presence and absence of added MEP antigen, the killing of 8/5)31 was significantly greater than killing of the control M/K) 16 We and others (7, 18) have shown that, before the onset of microbiologically documented P. aeruginosa infection, CF patients have detectable levels of serum antibody to MEP. Levels rise considerably once chronic infection is established (7, 18, 41, 42) . Indeed, circulating nonopsonic antibodies to MEP are routinely found in all non-CF humans examined (9, 18), as well as in infants > 6 mo of age (unpublished observation). Thus it seems possible that upon infection with P. aeruginosa, elaboration of the MEP antigen would result in the formation ofimmune complexes between antigen and preexisting nonopsonic antibodies, and these could mediate cytotoxic T cell killing of B cells that otherwise would secrete opsonic antibodies that could participate in bacterial killing and elimination. We believe the absence of these opsonic antibodies may be important in establishing chronic infections by mucoid P. aeruginosa in CF patients. This idea is consistent with our finding that colonized CF patients uniformly lack opsonic antibodies to MEP (9). Pedersen et al. (43) have shown that CF patients harboring strains ofP. aeruginosa that are phenotypically nonmucoid in vitro nonetheless respond to infection with antibody to MEP. This in vivo finding followed our initial observation (44) and that of Anastassiou et al. (45) that nonmucoid strains of P. aeruginosa elaborate small quantities of MEP antigen in vitro. Thus the nonmucoid strains that are thought to initially colonize CF patients may elaborate sufficient quantities of MEP in vivo that can complex with preexisting nonopsonic antibody and arm activated T cells to kill B cells that otherwise would produce protective, opsonic antibodies to this antigen. Under these conditions the mucoid form of P. aeruginosa can emerge and escape elimination by host defenses.
We observed that CF patients colonized with mucoid P. aeruginosa had high levels of circulating immune complexes that could sensitize Con A-activated human T cells for cytotoxic killing ofmurine hybridomas. However, we did not determine if CF patients have comparable cytotoxic T cells. It is likely that such T cells are present and active at a time and in a fashion that would allow chronic P. aeruginosa infection to be established. The likelihood that CF patients have CD8+ activated T cells is supported by the findings of Smith et al. (46) , who showed that lymphocytes from CF patients with chronic P. aeruginosa infection had greater levels of antibody-dependent cellular cytotoxicity directed against antibody-coated Chang cells compared with lymphocytes from noncolonized patients. This indicates that infected patients have activated lymphocytes that can kill eukaryotic target cells.
In conclusion, using surface immune complexes as the recognition unit, T cells from mice immunized with 50 jzg ofMEP from P. aeruginosa can kill hybridoma cells secreting opsonic antibody to this antigen. A similar kind of immune complex is found in the blood ofCF patients colonized with P. aeruginosa, and this complex can arm Con A-activated human T cells to kill the same target hybridomas. Immune complexes mediating cytotoxic activity were absent among younger CF patients lacking P. aeruginosa colonization, but the antibody component of these immune complexes was present, indicating the potential for rapid development of cytotoxic. cells against B cells once antigen is introduced at high enough levels by the onset of colonization and/or infection. We believe this to be a potential mechanism that allows mucoid P. aeruginosa to escape the host defenses of CF patients. 
